Short dual antiplatelet therapy duration in high bleeding risk patients undergoing PCI for non-ST-elevation acute coronary syndrome

27 August 2022 (17:15 - 18:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Davide Cao

Humanitas University, Milan (Italy)

7 More presentations in this session

Presentation thumbnail

CYP2C19 loss-of-function alleles and the use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel - a real-world study

Mr M. Ritvos (Helsinki, FI)

Abstract Slides

Presentation thumbnail

Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro

Professor B. Curry (Memphis, US)

Abstract Slides

Presentation thumbnail

Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention

Doctor M. Centore (Salerno, IT)

Abstract Slides

Presentation thumbnail

Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis

Doctor R. Turgeon (Vancouver, CA)

Abstract Slides

Presentation thumbnail

Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: a systematic review and meta-analysis

Doctor A. Apostolos (London, GB)

Abstract Slides

Access the full session

Session thumbnail

Short and long-term antiplatelet therapy in clinical practice

The Event

Event poster

ESC Congress 2022

27 August 2022 17:15 CET

You may be interested in

Webinar

Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

Congress Presentation

Antithrombotic therapy in diabetes

Congress Session

State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources